Cart summary

You have no items in your shopping cart.

    COVID-19 & SARS-CoV S glycoprotein antibody

    Catalog Number: orb669766

    DispatchUsually dispatched within 5-10 working days
    $ 531.00
    Catalog Numberorb669766
    CategoryAntibodies
    DescriptionMouse monoclonal antibody to COVID-19 & SARS-CoV S glycoprotein
    Species/HostHuman
    ClonalityMonoclonal
    Clone NumberCR3022
    Tested applicationsELISA, IF
    ReactivityVirus
    IsotypeIgG1
    ImmunogenThe original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
    Concentration1 mg/ml
    PurityPurified
    ConjugationUnconjugated
    TargetCOVID-19 & SARS-CoV S glycoprotein
    UniProt IDP59594
    StorageStore at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
    Buffer/PreservativesPBS with 0.02% Proclin 300.
    Alternative namesSpike protein, COVID19, COVID 19, S protein, SARS-
    Read more...
    NoteFor research use only
    Application notesThis antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.
    Expiration Date12 months from date of receipt.
    COVID-19 & SARS-CoV S glycoprotein antibody

    Line graph illustrates about the Ag-Ab reactions using different concentrations of antigen and serial dilutions of COVID-19 & SARS-CoV S glycoprotein antibody

    COVID-19 & SARS-CoV S glycoprotein antibody

    Line graph illustrates about the Ag-Ab reactions using different concentrations of antigen and serial dilutions of COVID-19 & SARS-CoV S glycoprotein antibody

    COVID-19 & SARS-CoV S glycoprotein antibody

    Line graph illustrates about the Ag-Ab reactions using different concentrations of antigen and serial dilutions of COVID-19 & SARS-CoV S glycoprotein antibody

    Submit a review

    Filter by Rating

      • Star
      • Star
      • Star
      • Star
      • Star
      • 5 stars
      • Star
      • Star
      • Star
      • Star
      • Star
      • 4 stars
      • Star
      • Star
      • Star
      • Star
      • Star
      • 3 stars
      • Star
      • Star
      • Star
      • Star
      • Star
      • 2 stars
      • Star
      • Star
      • Star
      • Star
      • Star
      • 1 stars